Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 18;9(1):37.
doi: 10.1186/s40164-020-00195-x.

Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country

Ana Muntañola  1 , Guillermo Villacampa  2   3 , José Ángel Hernández-Rivas  4 , Rosalía Alonso  5 , Fátima Mirás  6 , Santiago Osorio  7 , Mónica Baile  8 , Patricia Baltasar  9 , Javier López Jiménez  10 , Ines Hernandez-Rodriguez  11 , Susana Valenciano  12 , Ana Alfayate  13 , Eva Gimeno  14 , Abelardo Bárez  15 , Ana C Oliveira  16 , Rosalía Riaza  17 , Pilar Romero  18 , Julio Delgado  19 , Lucrecia Yáñez  20 , Amaya Zabalza  21 , Ana Torres  22 , Mª Isabel Gómez-Roncero  23 , Marta Crespo  24 , Raúl Córdoba  25 , Juan José Mateos-Mazón  26 , Sonia Pérez  27 , Rafael Andreu  28 , Jorge Labrador  29 , Mª Elena Ruiz  30 , César Andrés Velasquez  31 , Mª José Terol  32 , Raquel Santiago  33 , Mª Jesús Vidal  34 , Fiz Campoy García  35 , Lucía Villalón  36 , Begoña S Muiña  37 , Joan Alfons Soler  38 , Cristina Seri  39 , Mª José Sánchez  40 , Amalia Cuesta  41 , Rafael Ramos  42 , Adrián Sánchez-Montalvá  24 , Isabel Ruiz-Camps  24 , Marcos González  8 , Pau Abrisqueta  43 , Francesc Bosch  24 ; of the GELLC (Grupo Español de Leucemia Linfática Crónica)
Affiliations

Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country

Ana Muntañola et al. Exp Hematol Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declares no competing interest.

Figures

Fig. 1
Fig. 1
Overall survival curves according to (a) age, (b) Lymphocyte count, (c) D-dimer levels, and (d) BTKi treatment
Fig. 2
Fig. 2
Mortality rates in different groups of age comparing admitted patients with CLL to (a) patients admitted at University Hospital Vall d’Hebron Campus, Barcelona and (b) general population diagnosed with COVID19 in Spain
See this image and copyright information in PMC

References

    1. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed
    1. Gobierno de España. Ministerio de Sanidad. https://cnecovid.isciii.es/covid19/.
    1. Cuneo A, Scarfò L, Reda G, et al. Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. Blood. 2020;136(6):763–766. doi: 10.1182/blood.2020006854. - DOI - PMC - PubMed
    1. Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126(5):573–581. doi: 10.1182/blood-2015-03-567388. - DOI - PubMed
    1. Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter, international experience. Blood. 2020;136(10):1134–1143. doi: 10.1182/blood.2020006965. - DOI - PMC - PubMed

LinkOut - more resources